Ascendis Pharma A (ASND) EBT Margin (2014 - 2026)

Ascendis Pharma A has disclosed EBT Margin across 13 years of filings, most recently posting 19.54% for Q1 2026.

• EBT Margin for Q1 2026 came in at 19.54%, up 7314.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.69% (up 5837.0% YoY), and the FY2025 annual result was 29.53%, up 6245.0% from the prior year.
• EBT Margin came in at 19.54% for Q1 2026 at Ascendis Pharma A, down from 8.17% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 8.17% in Q4 2025 to a low of 1834.46% in Q1 2022.
• The 5-year median for EBT Margin is 169.76% (2024), against an average of 405.2%.
• Peak annual rise in EBT Margin reached 1183392 bps in 2022, while the deepest fall reached 74574 bps in 2022.
• Ascendis Pharma A's EBT Margin stood at 882.6% in 2022, then soared by 96 bps to 33.37% in 2023, then soared by 56 bps to 14.81% in 2024, then jumped by 45 bps to 8.17% in 2025, then slumped by 139 bps to 19.54% in 2026.
• The last three EBT Margin figures came in at 19.54% (Q1 2026), 8.17% (Q4 2025), and 26.86% (Q3 2025), per Business Quant data.